8 月国内合计批签发血制品763.67 万瓶，同比下降19.49%；1-8 月国内累计批签发血制品6800.36 万瓶，同比增长23.49%。

1.月度批签发数据跟踪 ................................................................................................................................................ 7

1.1 总批签发情况............................................................................................................................................................ 7

1.2 各品种批签发情况 .................................................................................................................................................... 7

2. 各品种批签发数据跟踪 ................................................................................................................................................. 8

2.1 人血白蛋白................................................................................................................................................................ 8

2.2 静注人免疫球蛋白（PH4） ................................................................................................................................... 10

2.3 人免疫球蛋白...........................................................................................................................................................11

2.4 乙型肝炎人免疫球蛋白 .......................................................................................................................................... 12

2.5 破伤风人免疫球蛋白 .............................................................................................................................................. 13

2.6 狂犬病人免疫球蛋白 .............................................................................................................................................. 14

2.7 人凝血因子VIII ...................................................................................................................................................... 15

2.8 人凝血酶原复合物 .................................................................................................................................................. 16

2.9 人纤维蛋白原 .......................................................................................................................................................... 17

3.上市公司批签发数据跟踪 ...................................................................................................................................... 18

3.1 上海莱士 .................................................................................................................................................................. 18

3.2 华兰生物 .................................................................................................................................................................. 19

3.3 天坛生物 .................................................................................................................................................................. 20

3.4 卫光生物 .................................................................................................................................................................. 21

3.5 博雅生物 .................................................................................................................................................................. 22

3.6 双林生物 .................................................................................................................................................................. 23

4.投资建议 ......................................................................................................................................................................... 24

5.风险提示 ......................................................................................................................................................................... 25